Cargando…

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452300/ https://www.ncbi.nlm.nih.gov/pubmed/34414680 http://dx.doi.org/10.1002/psp4.12698

Ejemplares similares

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
por: Gupta, Neeraj, et al.
Publicado: (2020)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
por: Gupta, Neeraj, et al.
Publicado: (2022)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers [Corrigendum]
Publicado: (2023)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Corrigendum to “Amiodarone Induced Hyponatremia Masquerading as Syndrome of Inappropriate Antidiuretic Hormone Secretion by Anaplastic Carcinoma of Prostate”
por: Dutta, Pinaki, et al.
Publicado: (2018)

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison
por: Yu, Yongfeng, et al.
Publicado: (2022)

Corrigendum to “Radiological Features of Gastrointestinal Lymphoma”
por: Lo Re, Giuseppe, et al.
Publicado: (2016)

Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
por: Högnäsbacka, Antonia A., et al.
Publicado: (2023)

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
por: Christopoulos, Petros, et al.
Publicado: (2021)

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
por: Yoshida, Tatsuya, et al.
Publicado: (2023)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Anaplastic lymphoma kinase–positive anaplastic large cell lymphoma presenting as diffuse pulmonary infiltrates
por: Sato, Shuku, et al.
Publicado: (2020)

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2018)

A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis
por: Li, Jisong, et al.
Publicado: (2018)

Anaplastic Lymphoma Kinase- and CD30-Positive Anaplastic Large-Cell Lymphoma of the External Auditory Canal
por: Chen, Shih-Lung, et al.
Publicado: (2021)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2022)

Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma Arising in a Patient with Hypersensitivity to Mosquito Bites
por: Kang, Jin Hee, et al.
Publicado: (2015)

Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
por: Xu, Wendan, et al.
Publicado: (2018)

Developing a Registry of Healthcare-Associated Infections at Intensive Care Units in West China: Study Rationale and Patient Characteristics [Corrigendum]
Publicado: (2020)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma
por: Morgan, Elizabeth A., et al.
Publicado: (2012)

A Case of Anaplastic Lymphoma Kinase-positive Large B-cell Lymphoma
por: Gupta, Gaurav K., et al.
Publicado: (2019)

Corrigendum to: Parallel Evolution of Complex Centipede Venoms Revealed by Comparative Proteotranscriptomic Analyses
por: Jenner, Ronald A, et al.
Publicado: (2021)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report
por: Kothari, Shalin, et al.
Publicado: (2016)

Primary bone anaplastic lymphoma kinase positive anaplastic large-cell lymphoma: A case report and review of the literature
por: Zheng, Wei, et al.
Publicado: (2021)

Soft-Tissue Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Child Unmasked by COVID-19
por: Lozano-Jaramillo, Diego Alberto, et al.
Publicado: (2023)

Corrigendum to “Synergistic Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide and Sorafenib against Cancer Stem Cells, Anaplastic Thyroid Cancer” [Neoplasia 19 (2017) 145-153]
por: Park, Ki Cheong, et al.
Publicado: (2017)

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
por: Tian, Chen, et al.
Publicado: (2016)

Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity
por: Tadokoro, Tomonori, et al.
Publicado: (2023)

Corrigendum to “Enamel Thickness before and after Orthodontic Treatment Analysed in Optical Coherence Tomography”
por: Machoy, Monika, et al.
Publicado: (2020)

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations [Corrigendum]
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1m8d29mlertkuiddt2ucqs8u2h